Sara Tolaney

🌐 YWF 2025 – Facing tough questions in cancer care 🎤 Dr. Nancy Lin | @DanaFarber 📅 26 July | ⏰ 18:15–18:45 GST 💡 Brain Metastasis Only Disease: Wrapping Our Heads Around It Explore new insights in metastatic breast cancer. 🔗 ywforum.com/registration/ #YWF2025 #BreastCancer

Young & Strong, the Program for Young Adults with Breast Cancer, is developing new tools, resources, and a refreshed website designed with you and your loved ones in mind. Please take two minutes to complete this survey to share your voice and experiences. Your confidential input…

Terrific closing for the @NRGonc ADC symposium, with Lauren Price from the @US_FDA highlighting the evolution of dose-optimization strategies for ADCs. Lots of work ongoing to identify the RIGHT dose of ADC treatments as EARLY as possible during development.

We are leading a randomized Phase 2 trial for stage 1 HER2+ #BreastCancer of T-DM1 followed by SQ trastuzumab versus TH (paclitaxel + SQ trastuzumab) (ATEMPT 2.0). ​ For more information call 877-338-7425 or visit:​ dana-farber.org/clinical-trial…

Check out this first-in-human phase 1/2 study of #palazestrant, a novel oral complete estrogen receptor antagonist (#CERAN) and selective estrogen receptor degrader (#SERD), in patients with ER+/HER2- advanced or #MetastaticBreastCancer. 🔓pubmed.ncbi.nlm.nih.gov/40598566/ @ErikaHamilton9…

Join me, along with my brilliant oncologist Dr @hoperugo, and @stolaney1 @irenekangmd @VeronicaJonesMD for the next @cityofhope breast cancer forum, Monday 7/28 5PM Pacific/8 PM Eastern, when we talk about more updates from #ASCO25 cityofhope.zoom.us/webinar/regist…

Biomarkers of Response and Resistance to Immune Checkpoint Inhibitors in Breast Cancer thebreastonline.com/article/S0960-…

Drs. Sarah Sammons (@drsarahsam) and Kristina Fanucci (@KristinaFanucci) recently updated our consensus based #TreatmentGuideline on the use of #Capivasertib plus #Fulvestrant in patients with advanced estrogen receptor-positive #BreastCancer. 👉physicianresources.dana-farber.org/flexpaper/capi… #MBC…

Don't miss Dr. Ana Garrido-Castro at the Memorial Cancer Institute’s Best of #ASCO25 symposium on Aug 1st where she will discuss #TNBC and #Immunotherapy. And on Aug 2nd at the Show Me the Data® satellite symposium on New and Emerging Roles for #OralSERD Therapy in the Treatment…

New in @CCR_AACR: Neoadj. CT+IO improves pCR, EFS & OS in TNBC, but among those who relapse, most do so early (<24m)—especially in pts with residual disease (see below). Urgent need for trials in this high-risk group: ICI+ADC? ICI+VEGF? Bispecifics? 🔗 doi.org/10.1158/1078-0…

Don't miss this new meta-analysis hot off the press in @TheLancetOncol! 👉#HER2DX and survival outcomes in early-stage HER2-positive #BreastCancer. Open access until Sept 2, 2025 🔓authors.elsevier.com/c/1lR4w5EIIgTS… ✍️@stolaney1 @TomasPascualMD @PTarantinoMD @JavierCortesMD @vitti10…

Game-changer from the POETIC study! 2 weeks of AI in ER+/HER2+ breast cancer: ✅79% of luminal B tumors shifted to luminal A ✅Those who shifted = 5x lower relapse risk (HR=0.2) ✅Luminal A? ET alone may be enough ⛔️Still B? Add CDK4/6i thelancet.com/journals/ebiom… #POETIC…

🆕review in press: Cancer of unknown primary site and TNM staging: A new paradigm for patient management doi.org/10.1016/j.anno…

Check out this npj Breast Cancer review: Unveiling the paradigm shift: Systemic treatment strategies in small, node-negative #BreastCancer 🔓pubmed.ncbi.nlm.nih.gov/40379683/ @marianascarant1 @renata_bonadio @DrRBarroso

Mark your calendars for PER’s School of Breast Oncology (SOBO), November 6-8, 2025! Register for FREE using my last name (TOLANEY) as a discount code! I always learn so much from this incredible course! #gotoPER #SOBO25 gotoper.com/courses/school…

🆕review in press: Clinical challenges and proposed solutions for patients with invasive lobular breast cancer @ChristineDesme2 doi.org/10.1016/j.anno…

🚨Just out in @CCR_AACR our analysis on the recurrence timing after neoadjuvant chemo-immunotherapy in early-stage TNBC We analyzed 5 major trials 👉 Early relapse: up to 83% of all recurrences🤯 1/ 🧵 Why this matters 👇 🔗 Full article: doi.org/10.1158/1078-0…

HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis buff.ly/1loYQqK A comprehensive individual patient-level meta-analysis of over 2,500 patients from 11 studies demonstrated that the HER2DX genomic test…

KAT6 Inhibition Shows Path to Overcoming Resistance Mechanisms in ER+ Breast Cancer @BostonChildrens @DanaFarber #bcsm #oncology onclive.com/view/kat6-inhi…

@DFCI_BreastOnc is leading the ADEPT study, examining the non-chemotherapy combination of HER2-directed therapy (trastuzumab and pertuzumab) + hormonal therapy as a treatment after surgery for early HR+/HER2+ #BreastCancer. Call 877-338-7425 or visit:​ dana-farber.org/clinical-trial…